BioNTech founders exit triggers share drop amid bold 2030 strategy
BioNTech's co-founders, Ugur Sahin and Özlem Türeci, have announced plans to leave the company. The news triggered an immediate fall in the firm's share price as investors reacted to the leadership change.
The departure was revealed alongside a broader strategy update on 10 March 2026. BioNTech outlined its ambition to become a multi-product company by 2030, with a new founder-led venture focusing on next-generation mRNA technology. As part of this shift, the firm also confirmed a strategic acquisition of CureVac to strengthen its research in oncology and other fields.
Despite the leadership transition, BioNTech retains a strong financial position, with billions in reserves and a deep drug development pipeline. However, the announcement has left investors uncertain about the company's future performance without Sahin and Türeci at the helm.
The share price dip reflects market concerns over BioNTech's direction following the founders' exit. The company's long-term plans now hinge on its ability to execute the 2030 strategy while maintaining investor confidence. The acquisition of CureVac and ongoing pipeline projects will be key to its next phase.
